|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001973,
umls-concept:C0027360,
umls-concept:C0034801,
umls-concept:C0087111,
umls-concept:C0205419,
umls-concept:C0596382,
umls-concept:C0871261,
umls-concept:C1274040,
umls-concept:C1335671,
umls-concept:C1417962,
umls-concept:C1417963,
umls-concept:C1417965,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2007-3-21
|
|
pubmed:abstractText |
Pharmacotherapy of alcohol dependence (AD) is at an early stage of development; currently available medications have limited efficacy. It would be clinically valuable to identify, before initiation of a course of treatment, those patients who, based on genetic markers, are most likely to respond to a specific pharmacotherapy. A previous report suggested that a functional variant at the genetic locus encoding the mu opioid receptor (Asn40Asp) is such a marker, in short-term (3-month) treatment with the opioid-blocking drug naltrexone (NTX).
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/DNA,
http://linkedlifedata.com/resource/pubmed/chemical/Naltrexone,
http://linkedlifedata.com/resource/pubmed/chemical/Narcotic Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/OPRK1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/OPRM1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Opioid, delta,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Opioid, kappa,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Opioid, mu
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0145-6008
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
31
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
555-63
|
|
pubmed:dateRevised |
2008-11-21
|
|
pubmed:meshHeading |
pubmed-meshheading:17374034-Adult,
pubmed-meshheading:17374034-Alcoholism,
pubmed-meshheading:17374034-Confidence Intervals,
pubmed-meshheading:17374034-DNA,
pubmed-meshheading:17374034-Double-Blind Method,
pubmed-meshheading:17374034-Exons,
pubmed-meshheading:17374034-Female,
pubmed-meshheading:17374034-Genetic Variation,
pubmed-meshheading:17374034-Genotype,
pubmed-meshheading:17374034-Humans,
pubmed-meshheading:17374034-Linear Models,
pubmed-meshheading:17374034-Logistic Models,
pubmed-meshheading:17374034-Male,
pubmed-meshheading:17374034-Middle Aged,
pubmed-meshheading:17374034-Naltrexone,
pubmed-meshheading:17374034-Narcotic Antagonists,
pubmed-meshheading:17374034-Odds Ratio,
pubmed-meshheading:17374034-Proportional Hazards Models,
pubmed-meshheading:17374034-Psychiatric Status Rating Scales,
pubmed-meshheading:17374034-Receptors, Opioid, delta,
pubmed-meshheading:17374034-Receptors, Opioid, kappa,
pubmed-meshheading:17374034-Receptors, Opioid, mu,
pubmed-meshheading:17374034-Smoking,
pubmed-meshheading:17374034-Treatment Outcome,
pubmed-meshheading:17374034-United States,
pubmed-meshheading:17374034-United States Department of Veterans Affairs
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study.
|
|
pubmed:affiliation |
VA Connecticut Healthcare System, West Haven Campus, West Haven, Connecticut 06516, USA. joel.gelernter@yale.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, Non-P.H.S.,
Randomized Controlled Trial,
Research Support, N.I.H., Extramural
|
